Radiodermititis Market By Product type | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Radiodermititis Market
Radiodermititis Market: By Product type (Topical, Oral Medication and Dressings), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy Store, and Online Store) & By Region-Forecast (2016-2021)
Report Code : HCR 0363
Updated Date: 19 August, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Radiodermititis Market – Market Overview
2. Executive Summary 
3. Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Radiodermititis Market– Market Forces
   4.1. Drivers
      4.1.1. Technological Advancement
      4.1.2. Growing Number of Cancer Patients
   4.2. Restraints
      4.2.1. Lack of Adequate Infrastructure & Healthcare Expenditure
   4.3. Opportunities
      4.3.1. Emerging Markets Offer Numerous Growth Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Radiodermititis Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Radiodermititis Market, By Product Type
   6.1. Topical
   6.2. Oral Medication
   6.3. Dressings
   6.4. Others
7. Radiodermititis Market, By Distribution Channel
   7.1. Hospital Pharmacy
   7.2. Retail Pharmacy Store
   7.3. Online Store
   7.4. Others
8. Radiodermititis Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America 
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Radiodermititis – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. 3M Health Care
   10.2. BMG Pharma
   10.3. Molnlycke Health Care
   10.4. Smith & Nephew plc
   10.5. Derma Sciences, Inc.
   10.6. Alliqua Biomedical
   10.7. Acelity LP
   10.8. Intermed Pharmaceuticals
   10.9. Stratpharma AG
   10.10. Bayer Healthcare
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Radiodermatitis, also commonly referred to as radiation dermatitis in medical terminology, is a symptom caused as result of using radiation therapy used to treat cancer as well as exposure to radiation during nuclear disasters. While treating cancer with radiotherapy, cumulative daily doses of radiation are given to the treatment field or target site on the body prevent normal skin to repopulate and weakens the skin integrity at and around the radiation field. Degree of radiodermatitis may be acute or chronic and encompasses localized erythema, skin shedding (desquamation), hair loss (epilation), fibrosis, necrosis, and other similar conditions. According to the WHO, the number of new patients of cancer is expected to grow by 70% in the next two decades. The growing number of cancer patients around the world is the chief driving force behind the radiodermititis market’s growth however higher cost and adequate infrastructure in the major parts of the world is expected to be key restraining factor for the radiodermititis market.

 Radiodermititis Market

Geographically Asia-Pacific dominated radiodermititis market driven by best in the developing healthcare infrastructure, increasing awareness, increasing cancer patients and growing spending by the citizens towards healthcare expenditure. Asia-Pacific was followed by Europe and North America as second and third largest market for radiodermititis market. Asia Pacific is projected to have fastest growth, owing to rapidly increasing healthcare infrastructure, increased spending, government initiatives and increasing awareness amongst population, and growing medical tourism industry in developing nations such as China, and India in this region.

This report identifies the global radiodermititis market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global radiodermititis market.

This report segments radiodermititis market on the basis of product type, distribution channel type and regional market as follows:
  • Radiodermititis Market, By Product Type: Topical, Oral Medication, Dressings and others
  • Radiodermititis Market, By Distribution channel: Hospital Pharmacy, Retail Pharmacy Store, Online Store and others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the radiodermititis market. Some of the major companies’ profiles in detail are as follows:
  • 3M Health Care
  • BMG Pharma
  • Molnlycke Health Care
  • Smith & Nephew plc
  • Derma Sciences, Inc.
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports